Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
RALEIGH, N.C., Oct. 19, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully-integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract Commercial Organization), will release its third quarter 2017 financial results on Thursday, November 9, 2017, prior to its earnings call at 8:00 a.m. EST.
Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website at investor.incresearch.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 3396217.
A webcast replay will be available on the Investor Relations section of the INC Research website at investor.incresearch.com after 1:00 p.m. on November 9. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 3396217.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745
[email protected]
Press/Media Contact:
Danielle DeForge
Senior Director, External Communications
+1 781 425 2624
[email protected]
